These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12359859)

  • 1. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Foulkes WD; Goffin J; Brunet JS; Bégin LR; Wong N; Chappuis PO
    J Natl Cancer Inst; 2002 Oct; 94(19):1504-6. PubMed ID: 12359859
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
    J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
    Neven P; Paridaens R; Amant F; Wildiers H; Berteloot P; Leunen K; Smeets A; Weltens C; van den Bogaert W; van Limbergen E; Christiaens MR; Vergote I
    Int J Gynecol Cancer; 2006; 16 Suppl 2():505-10. PubMed ID: 17010059
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
    Ito Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
    [No Abstract]   [Full Text] [Related]  

  • 5. With maturity comes confidence: EBCTCG tamoxifen update.
    Chia SK; Wolff AC
    Lancet; 2011 Aug; 378(9793):747-9. PubMed ID: 21802719
    [No Abstract]   [Full Text] [Related]  

  • 6. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
    J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen therapy--long-term results and complications.
    Moore MP; Kinne DW
    Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
    [No Abstract]   [Full Text] [Related]  

  • 8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 10. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina V
    Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
    [No Abstract]   [Full Text] [Related]  

  • 12. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
    Sano M; Makino H
    Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Atkins CD
    J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
    [No Abstract]   [Full Text] [Related]  

  • 14. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT; Andersen J
    Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer: new aspects of adjuvant hormonal therapy.
    Lohrisch C; Piccart M
    Ann Oncol; 2000; 11 Suppl 3():13-25. PubMed ID: 11079114
    [No Abstract]   [Full Text] [Related]  

  • 18. Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
    O'Leary CG; Ellis H; Higgins M
    Curr Opin Oncol; 2016 Nov; 28(6):455-460. PubMed ID: 27606696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
    Eisinger F; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Julian-Reynier C; Sobol H
    Int J Oncol; 2001 Jan; 18(1):5-10. PubMed ID: 11115532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
    Cerne JZ; Zong L; Jelinek J; Hilsenbeck SG; Wang T; Oesterreich S; McGuire SE
    Breast Cancer Res Treat; 2012 Aug; 135(1):135-43. PubMed ID: 22706629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.